Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Stephanie Guidez (1) , Guillemette Fouquet (1) , Helene Demarquette (1) , Morgane Nudel (1) , Eileen Boyle (1) , Marie Lorraine Chretien , Denis Caillot (2) , Lionel Karlin (3) , Cyrille Hulin (4) , Olivier Decaux (5) , Bertrand Arnulf (6) , Cecile Fohrer , Margaret Macro (7) , Charles Lancesseur , Murielle Roussel (8) , Benjamin Hebraud , Thierry Facon (1) , Xavier Leleu (9, 1)

1 Hôpital Claude Huriez [Lille]
2 CHU Dijon
3 Service d'immunologie
4 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
5 IGDR - Institut de Génétique et Développement de Rennes
6 Service d'hématologie biologique
7 Hôpital Universitaire de Caen
8 CHU Pontchaillou [Rennes]
9 Centre Hospitalier de Valenciennes

55th Annual Meeting and Exposition of the American-Society-of-Hematology - New Orleans, LA 2013

Domains: Life Sciences [q-bio]

Stephanie Guidez, Guillemette Fouquet, Helene Demarquette, Morgane Nudel, Eileen Boyle, et al.. Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma. Blood, 2015, 126 (23), pp.5379. ⟨hal-01290429⟩